STOCK TITAN

Vaxcyte, Inc. (PCVX) CTO sells 17,000 shares under 10b5-1 plan

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vaxcyte, Inc. executive Harpreet S. Dhaliwal, Chief Technical Ops Officer, reported an option exercise and related share sale. On August 5, 2026, he exercised stock options covering 17,000 shares of common stock at an exercise price of $24.79 per share from a fully vested option grant, and reported holding 28,000 stock options after the transaction.

The same day, he sold 17,000 common shares at a weighted-average price of $55.004 per share, with trade prices ranging from $55.00 to $55.255, under a Rule 10b5-1 trading plan adopted on April 6, 2026. His reported direct common stock position includes 780 shares acquired through the Employee Stock Purchase Plan on May 15, 2026.

Positive

  • None.

Negative

  • None.
Insider Dhaliwal Harpreet S.
Role Chief Technical Ops Officer
Sold 17,000 shs ($935K)
Approx. gross sale proceeds $935K
Approx. exercise cost $421K
Approx. pre-tax spread $514K
Type Security Shares Price Value
Exercise Stock Option (right to buy) F4 17,000 $0.00 $0.00
Exercise Common Stock F1 17,000 $24.79 $421K
Sale Common Stock F2, F3 17,000 $55.004 $935K
Holdings After Transaction: Stock Option (right to buy) — 28,000 shares (Direct); Common Stock — 76,756 shares (Direct)
Footnotes (4)
  1. F1. Includes 780 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.
  2. F2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 6, 2026.
  3. F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.00 to $55.255. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. F4. Stock Option is fully vested and exercisable.
Options exercised 17,000 shares Stock options converted into common stock on August 5, 2026
Exercise price $24.79 per share Strike price for the 17,000-share stock option exercised
Shares sold 17,000 shares Common stock sold on August 5, 2026 following the option exercise
Weighted-average sale price $55.004 per share Sale of 17,000 shares; trades ranged from $55.00 to $55.255
Options remaining 28,000 shares Stock options reported held after the 17,000-share exercise
ESPP shares 780 shares Shares acquired under the Employee Stock Purchase Plan on May 15, 2026
Rule 10b5-1 trading plan financial
"sales reported were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported is a weighted-average price. The shares were sold at prices"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Employee Stock Purchase Plan financial
"Includes 780 shares acquired under the Issuer's Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Stock Option financial
"Stock Option is fully vested and exercisable."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What transactions did Vaxcyte (PCVX) executive Harpreet S. Dhaliwal report?

Harpreet S. Dhaliwal reported exercising options for 17,000 Vaxcyte shares at $24.79 and selling 17,000 shares at a weighted-average $55.004 on August 5, 2026. The exercise reduced his option position and the sale occurred immediately after conversion.

Were Harpreet S. Dhaliwal’s PCVX share sales made under a Rule 10b5-1 plan?

Yes. The filing states the 17,000-share sale was effected under a Rule 10b5-1 trading plan adopted on April 6, 2026. Such pre-arranged plans allow insiders to schedule trades in advance, independent of later material nonpublic information.

What option holdings does Harpreet S. Dhaliwal report for Vaxcyte (PCVX)?

After exercising, Dhaliwal reported holding 28,000 stock options. The exercised option, covering 17,000 shares at $24.79, was fully vested and exercisable and carries an expiration date of March 2, 2032, according to the filing footnote.

At what prices were the Vaxcyte (PCVX) shares sold in this Form 4?

The 17,000 Vaxcyte shares were sold at a weighted-average price of $55.004 per share. A footnote explains individual trades occurred in a range from $55.00 to $55.255, and detailed trade breakdowns are available on request.

Does Harpreet S. Dhaliwal hold Vaxcyte (PCVX) shares from the Employee Stock Purchase Plan?

Yes. The filing notes his direct common stock holdings include 780 shares acquired under the Employee Stock Purchase Plan on May 15, 2026. This figure forms part of his overall reported common stock position.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dhaliwal Harpreet S.

(Last)(First)(Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300

(Street)
SAN CARLOS CALIFORNIA 94070

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technical Ops Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/05/2026M17,000A$24.7993,756(1)D
Common Stock08/05/2026S(2)17,000D$55.004(3)76,756D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$24.7908/05/2026M17,000 (4)03/02/2032Common Stock17,000$028,000D
Explanation of Responses:
1. Includes 780 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.
2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 6, 2026.
3. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.00 to $55.255. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
4. Stock Option is fully vested and exercisable.
Remarks:
Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)